Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIP | P01282 | 2/20 | 0.59 |
| ▸ | CBLB | Q13191 | 8/20 | 0.47 |
| ▸ | KCNA6 | P17658 | 2/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.41 |
| ▸ | KCNA4 | P22459 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.41 |
| ▸ | KCNA2 | P16389 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN4A | P35499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromoageliferin SCHEMBL30182244 | 0.88 | VIP (0.47) | VIPCBLBKCNA6KCNA3KCNA4 | |
| Bromoageliferin SCHEMBL12648889 | 0.78 | CBLB (0.47) | VIPCBLBKCNA6KCNA3KCNA4 | |
| Nagelamide E SCHEMBL29489927 | 0.77 | VIP (0.47) | VIPCBLBKCNA6KCNA3KCNA4 | |
| Sceptrin SCHEMBL31027459 | 0.75 | VIP (0.98) | VIPCBLBKCNA6KCNA3KCNA4 | |
| Sceptrin SCHEMBL31027460 | 0.75 | VIP (0.98) | VIPCBLBKCNA6KCNA3KCNA4 | |
| SCHEMBL12597859 | 0.74 | VIP (0.54) | VIPCBLBKCNA6KCNA3KCNA4 | |
| SCHEMBL12559790 | 0.74 | VIP (0.54) | VIPCBLBKCNA6KCNA3KCNA4 | |
| SCHEMBL12852200 | 0.74 | VIP (0.54) | VIPCBLBKCNA6KCNA3KCNA4 | |
| SCHEMBL12852189 | 0.73 | SCN9A (0.53) | CBLBKCNA6KCNA3KCNA4KCNA5 | |
| SCHEMBL12559784 | 0.73 | SCN9A (0.53) | CBLBKCNA6KCNA3KCNA4KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10292390-B2 | Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2019-05-21 | — | — | US | disclosed |
| US-20130136782-A1 | Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130136782-A1 | Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives | FLNB, BRI3BP, CCNI | VIP 2903/4885CBLB 405/4885KCNA6 2777/4885 |
| US-10292390-B2 | Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives | FLNB, BRI3BP, CCNI | VIP 2903/4885CBLB 405/4885KCNA6 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.